[AGRANULOCYTOSIS CAUSED BY APALUTAMIDE : A CASE REPORT].

Authors

Yuki Fujiwara, Kosuke Shibamori, Sho Nakayama

Published in

Hinyokika kiyo. Acta urologica Japonica. Volume 72. Issue 9. Pages 279-282.

Abstract

We report a case of agranulocytosis associated with apalutamide treatment in a patient with non-metastatic castration-resistant prostate cancer (nmCRPC). An 89-year-old man was diagnosed with prostate cancer (cT2cN0M0) four years earlier and treated with surgical castration and anti-androgen therapy. Subsequently, his PSA levels increased. Imaging studies showed no obvious metastases, and he was diagnosed with nmCRPC. Darolutamide was initiated but discontinued because of liver dysfunction, and treatment was switched to apalutamide. Forty-five days after the initiation of apalutamide, the patient presented with fatigue. Laboratory findings revealed severe neutropenia, with a neutrophil count of 54/μl, leading to a diagnosis of apalutamide-induced agranulocytosis. Apalutamide was discontinued, and granulocyte-colony stimulating factor (G-CSF) and antibiotics were administered. The neutrophil count recovered to the normal range 13 days after treatment. Clinicians should be aware of the potential risk of agranulocytosis when neutropenia develops during apalutamide therapy.

PMID:
42817762
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.